MEDVi alternatives: what else costs less or bills differently
As of November 20, 2026, MEDVi has no current month-to-month price that can be compared like for like (its compounded prices did not render on November 20, 2026 (the page showed template placeholders)), so the tables below list the programs that do print one.
Released · Last reviewed · how we verify
Tirzepatide: programs that print a comparable price
MEDVi cannot be placed on the like-for-like tirzepatide scale because its page shows no month-to-month figure that applies at the maintenance dose. These programs print a month-to-month, all-in tirzepatide price that applies at every dose or at the maintenance dose (read November 20, 2026).
| Program | Month to month, all-in | Basis | Year at that price | Lowest printed rate | Read |
|---|---|---|---|---|---|
| Collective | $85.58 | per month | $1,027 | $85.58 ($69 a month plus $199 a year) | 2026-11-20 |
| Mondae | $126 | per month | $1,512 | $114 (6-month plan, $684) | 2026-11-20 |
| NexLife | $129 | per month | $1,548 | $115 (12-month plan) | 2026-11-20 |
| Eden | $129 | per month | $1,548 | $129 (every month) | 2026-11-20 |
| Yucca Health | $139 | per month | $1,668 | $119 (12-month plan, $1,428 upfront) | 2026-11-20 |
| Fifty 410 | $199 | per 28-day cycle | $2,587 | $149.50 (8-week program at $299, not in all states) | 2026-11-20 |
| Emerge Weight Loss | $269 | per 28-day cycle | $3,497 | $224 (2.5 mg, per 4 weeks) | 2026-11-20 |
| OrderlyMeds | $299 | per month | $3,588 | $149 (2-month new-customer offer, $299) | 2026-11-20 |
Semaglutide: programs that print a comparable price
MEDVi cannot be placed on the like-for-like semaglutide scale because its page shows no month-to-month figure that applies at the maintenance dose. These programs print a month-to-month, all-in semaglutide price that applies at every dose or at the maintenance dose (read November 20, 2026).
| Program | Month to month, all-in | Basis | Year at that price | Lowest printed rate | Read |
|---|---|---|---|---|---|
| Collective | $75.58 | per month | $907 | $75.58 ($59 a month plus $199 a year) | 2026-11-20 |
| Mondae | $87 | per month | $1,044 | $69 (6-month plan, $414) | 2026-11-20 |
| Yucca Health | $89 | per month | $1,068 | $69 (12-month plan, $828 upfront) | 2026-11-20 |
| Eden | $99 | per month | $1,188 | $99 (every month) | 2026-11-20 |
| NexLife | $109 | per month | $1,308 | $95 (12-month plan) | 2026-11-20 |
| OrderlyMeds | $149 | per month | $1,788 | $74 (2-month new-customer offer, $149) | 2026-11-20 |
| Fifty 410 | $199 | per 28-day cycle | $2,587 | $199 (4-week program) | 2026-11-20 |
| Noom Med | $249 | per 28-day cycle | $3,237 | $249 (per 4 weeks, billed every 12 weeks) | 2026-11-20 |
Brand alternatives
FDA-approved brand medication bought direct costs more: Zepbound vials from $299 at 2.5 mg to $449 a month at 7.5–15 mg with refills inside 45 days (LillyDirect, ladder carried from October 15), and Wegovy pens $349 a month (NovoCare, read November 20, 2026). Insurance coverage of a brand drug usually beats any cash price; see the insurance page.
Limitations
Compounded tirzepatide and semaglutide are not FDA-approved and are not the same products as Zepbound or Wegovy. Switching programs means a new prescriber review; ask the new program how it handles your current dose.
Frequently asked
What is the main alternative to MEDVi?
As of November 20, 2026, MEDVi has no current month-to-month price that can be compared like for like (its compounded prices did not render on November 20, 2026 (the page showed template placeholders)), so the tables below list the programs that do print one.
How are alternatives chosen here?
By the same basis for every program: the compounded month-to-month, all-in price at the maintenance dose, read on the program’s own page on November 20, 2026, turned into a year’s cost (12 months, or 13 four-week cycles). Programs that print only a starting-dose or coupon price are listed separately, because their regular cost cannot be confirmed.
Sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026; read November 20, 2026)
- Federal Register 91 FR 23431: proposed 503B bulks-list decision for semaglutide, tirzepatide and liraglutide (May 1, 2026; no final notice found as of November 20, 2026)
- Zepbound (tirzepatide) prescribing information on DailyMed (read November 20, 2026)
- Wegovy (semaglutide) prescribing information on DailyMed (read November 20, 2026)
- MEDVi pricing page (not readable on November 20, 2026)
- FDA warning letter 721455 to MEDVi (dated 2026-02-20, posted 2026-03-03; read November 20, 2026)